Xenon Pharmaceuticals XENE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0-100% | $7.5M— | ||
| $88.51M+0.9% | $87.7M+13.8% | $77.05M+2.8% | $74.99M+22.5% | $61.2M+2.9% | ||
| $23.82M+7.9% | $22.07M+14.4% | $19.28M+0.2% | $19.24M+1.1% | $19.04M+5.7% | ||
| $112.33M+2.3% | $109.77M+13.9% | $96.34M+2.2% | $94.23M+17.4% | $80.24M+3.6% | ||
| -$112.33M-2.3% | -$109.77M-13.9% | -$96.34M-2.2% | -$94.23M-29.5% | -$72.74M+6.1% | ||
| $7.46M+47.8% | $5.04M-17.5% | $6.12M-31.2% | $8.9M+9.6% | $8.12M+2.2% | ||
| -$104.87M-0.1% | -$104.72M-16.1% | -$90.22M-5.7% | -$85.33M-32.1% | -$64.62M+7.1% | ||
| -$2.57M-578% | $538K-20.5% | $677K+208% | -$626K-247% | $427K+111% | ||
| -$102.3M+2.8% | -$105.26M-15.8% | -$90.9M-7.3% | -$84.71M-30.2% | -$65.05M+1.0% | ||
| -$1.17+10.7% | -$1.31-13.9% | -$1.15-7.5% | -$1.07-28.9% | -$0.83+1.2% | ||
| -$111.74M-2.4% | -$109.16M-14.1% | -$95.7M-2.2% | -$93.6M-29.9% | -$72.08M+6.2% | ||
| -$112.33M-2.3% | -$109.77M-13.9% | -$96.34M-2.2% | -$94.23M-29.5% | -$72.74M+6.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Xenon Pharmaceuticals profitable?
- Xenon Pharmaceuticals is not currently profitable: it reported a net loss of $383.2M over the trailing twelve months, a -4612.1% net margin.
- What is Xenon Pharmaceuticals's earnings per share?
- Xenon Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.70.
- Where does Xenon Pharmaceuticals's income statement data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.